PDPK2P and hepatocellular carcinoma: Based on the PDK1/AKT/caspase 3 pathway, lncRNA PDPK2P had interaction with PDK1 to promote HCC development, indicating it can act as a target gene for the therapy and prognosis of HCC [13].